WOBURN, Mass., Oct. 9 /PRNewswire/ -- Tandem Labs, a leading contract research organization (CRO) providing bioanalytical, immunoanalytical, and pharmacokinetic (PK)/pharmacodynamic (PD) services to the pharmaceutical industry, announced that it has acquired additional MDS SCIEX API 5000(TM) and 4000(TM) LC/MS/MS systems for its New England facility in Woburn, Massachusetts. This acquisition doubles the facility's current triple quadrupole LC/MS/MS capacity, allowing it to better serve its clientele through this expansion in capacity.
"Tandem Labs acquired these additional instruments to further increase our capacity in the critical New England region," said Denis C.K. Lin, Ph.D., president and CEO. "These assets will significantly enhance our reach within the drug discovery and development industry, particularly in Massachusetts as well as other Northeast states."
The New England operation is focused upon providing rapid turnaround non- GLP discovery PK/PD services in addition to metabolite identification and biomarker services. Combined with other advanced mass spectrometric platforms beyond the triple quadrupoles, the New England facility also uses proprietary informatics to reduce the difficulty, complexity, and time-consuming nature of developing and launching a drug to market. DMDiscovery(TM) is a drug metabolism technology that increases the productivity of drug metabolite identification and quantification. MarkerScan(TM) is a biomarker discovery and screening process that efficiently identifies potential biomarkers that can be used to increase the understanding of disease, diagnosis, and predictive models as well as drug compound safety, efficacy, and side-effect profiles.
Tandem Labs has additional facilities in Utah and New Jersey; the Utah
location focuses primarily on GLP bioanalytical services and discovery
support while the New Jersey location specializes in GLP-compliant
bioanalysis on LC/MS/MS and immunoanalytical platforms.<
|SOURCE Tandem Labs|
Copyright©2007 PR Newswire.
All rights reserved